Wavepaths, a London, UK-based producer of music for psychedelic therapy, raised $4.5m in its initial seed funding round.
Participants in the round included Heron Rock, Reflex Capital, Bridge Builders Collaborative, Palo Santo, Lionheart Ventures, Sanjay Singhal of the Nikean Foundation, Empath Ventures, Neo Kuma Ventures, Miton Psychonauts Fund, and Tabula Rasa Ventures, among others.
The funding will be used to further develop the company’s personalization and music-generation algorithms, scale the platform, and increase functionality for a wider range of healthcare practices.
Co-founded by Dr. Mendel Kaelen and Anna Rickman in 2019, Wavepaths is a digital platform that builds upon scientific research showing that music plays an essential role in creating positive outcomes for psychedelic therapies such as ketamine, psilocybin, and MDMA. Its advanced generative music system gives psychedelic therapy practitioners the tools to optimize therapeutic outcomes for their clients.
The company has worked with a variety of musical artists to create an AI-powered auditory landscape designed to be responsive to every moment of a therapy session. With Wavepaths, practitioners create unique soundscapes that channel the evocative sounds of visionary producers like Jon Hopkins, Greg Haines, Robert Rich, and Christina Vantzou. During sessions, the platform’s interface allows practitioners to transition between emotional atmospheres, levels of depth and activation, and instrumentation in real time, based on a patient’s evolving mood or therapeutic needs.
The company is working in close partnership with research institutions, universities, and psychedelic therapy companies to optimize therapeutic outcomes and improve the understanding of how music can contribute to the effectiveness of these therapies.
Wavepaths is currently being used in over 29 countries, with over 5,000 practitioners on the waiting list for the public release. The app is in closed beta, with its public release expected later this year.